Question: Activating mutations in a raf gene are common in driving the formation and maintenance of human m…

Activating mutations in a raf gene are common in
driving the formation and maintenance of human melanomas. Drugs
that target this hyperactive raf protein are initially effective in
combating this cancer. However, in some cases, additional
activating mutations in the raf gene occur and the melanoma cells
become resistant to the first drug.
Two companies are synthesizing secondary drugs to combat this
resistant melanoma. Company A has produced a drug that inhibits ras
activity, whereas Company B has produced a MEK inhibitor. Should
you buy stock in Company A or Company B (i.e. which company is
likely to have an effective drug for the resistant melanoma)?
Explain your choice.